GlassScriptPhysician profile
Brian Fertig
NPI 1528119146
$4,404.77
in general payments reported to CMS, 2019-2025
37 companies · $631 in 2025
The $631 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $502 · 2021: $619 · 2022: $982 · 2023: $396 · 2024: $965 · 2025: $631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,991.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,991.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,088.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Dexcom, INC. | $694.42 | 2021-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $591.18 | 2019-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $293.60 | 2024-2025 | |
| Medtronic Minimed, INC. | $181.88 | 2019-2020 | |
| Corcept Therapeutics | $163.09 | 2020-2025 | Korlym |
| Pfizer INC. | $149.86 | 2021-2025 | |
| Medtronic, INC. | $137.91 | 2021-2024 | Minimed 780g |
| Merck Sharp & Dohme LLC | $122.85 | 2019-2023 | Steglatro, Segluromet |
| Abbvie INC. | $92.20 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $92.14 | 2019-2024 | |
| Amneal Pharmaceuticals LLC | $83.30 | 2021-2025 | Unithroid |
| Mannkind Corporation | $78.81 | 2021-2024 | |
| Lilly USA, LLC | $74.04 | 2021-2025 | Mounjaro, Zepbound |
| Insulet Corporation | $60.54 | 2025 | Omnipod |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Fertig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.